ABSTRACT
In this study, we studied the activity of the antibacterial drugDoxycycline (Russia), and the control was the drug of pentavalent antimony - Glucantim (France), which for a long time was the "gold standard" in the treatment of any form of leishmaniasis. In the course of the experiment, the leading positions of doxycycline established in vitro. Its minimum doses lead to absolute suppression of the mobility of the pathogen L. major. Increasing the therapeutic dose of the drug is not justified. Comparison of this drug with the gold standard of therapy with meglumine antimonate (glucantim) showed its superiority in all indicators.
Subject(s)
Doxycycline/therapeutic use , Leishmaniasis/drug therapy , Meglumine Antimoniate/therapeutic use , Humans , In Vitro TechniquesABSTRACT
Helminth infestations, including trematodoses, are a group of the most common diseases in the world. Trematodoses cause significant damage to human health, lead to various complications, which also causes significant economic damage. To develop effective anthelmintic drugs, it is necessary to study the structure and physiology of parasites and interaction with the host body. To create specific anthelmintic drugs, it is necessary to study the features of biochemistry and molecular biology of the structural components of the covers of trematodes. The is important role of the tegument in the evasion of the immune response. The trematode tegument antigens are good candidates for the development of anthelmintic vaccines. It is important to study the trematode genome and identify specific enzyme systems. Proteases of tegument of trematodes are digestive enzymes that can destroy the immunoglobulins of the host to modulate the immune response. Identification of specific differences in protein and enzyme systems will create more effective drugs for the treatment of helminthiasis.
Subject(s)
Anthelmintics , Helminthiasis , Trematoda , Animals , Anthelmintics/pharmacology , Helminthiasis/drug therapy , Humans , Trematoda/drug effects , VaccinesABSTRACT
Malaria is one of the most important and common infectious diseases in the world. The world health organization estimates 225 million malaria cases worldwide. Malaria is one of the strongest selective factors affecting the human genotype. The greatest pressure of malaria pathogens had on the inhabitants of the tropical belt, in which invasion was the main factor of genetic selection. As a result, there were genetic diseases such as sickle cell anemia, thalassemia, glucose-6-phosphate dehydrogenase deficiency and others. An important role in the pathogenesis of malaria is the stage of penetration of the parasite of malarial Plasmodium into the erythrocyte. Changes in the structure of surface antigens of red blood cells may contribute to or reduce the effectiveness of invasion. Genetic polymorphism associated with the pathogenesis and characteristics of the malaria clinic is also important in the development of malaria resistance. Understanding the genetic changes associated with red blood cell disorders and pathogenesis can provide insights into the development of new strategies for malaria treatment and prevention.